

**PB 76 of 2025**

**National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 6)**

*National Health Act 1953*

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 98C(1) of the *National Health Act 1953*.

Dated 26 June 2025

**REBECCA RICHARDSON**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019) 2

1 Name

1. This instrument is the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2025 (No. 6)*.
2. This instrument may also be cited as PB 76 of 2025.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 July 2025 | 1 July 2025 |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 98C(1) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

*National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)*

1. Schedule 3, after entry for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 18 mg (extended release)

*insert:*

|  |  |
| --- | --- |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 18 mg (extended release) Concerta (Switzerland) (S19A) |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 18 mg (extended release) (S19A) |

1. Schedule 3, after entry for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 27 mg (extended release)

*insert:*

|  |  |
| --- | --- |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 27 mg (extended release) (S19A) |

1. Schedule 3, after entry for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 36 mg (extended release)

*insert:*

|  |  |
| --- | --- |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 36 mg (extended release) Concerta (Switzerland) (S19A) |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 36 mg (extended release) (S19A) |

1. Schedule 3, after entry for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 54 mg (extended release)

*insert:*

|  |  |
| --- | --- |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 54 mg (extended release) Concerta (Switzerland) (S19A) |
| Methylphenidate | Tablet containing methylphenidate hydrochloride 54 mg (extended release) (S19A) |

1. Schedule 4, omit entry for Dexamethasone
2. Schedule 4, after entry for Dorzolamide with timolol

*insert:*

|  |  |
| --- | --- |
| Drospirenone | Pack containing 24 tablets 4 mg and 4 inert tablets |

1. Schedule 4, omit entry for Hypromellose with carbomer 980
2. Schedule 4, after entry for Naproxen

*insert:*

|  |  |
| --- | --- |
| Naproxen | Oral suspension 125 mg per 5 mL, 474 mL (S19A) |